Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.
Cutera, Inc. (symbol: CUTR) is a leading innovator in the field of medical aesthetics, specializing in the design, development, manufacturing, marketing, and servicing of energy-based aesthetic systems. Established in 1998 by experienced laser and optical engineers in Brisbane, California, Cutera has grown to become a trusted authority in face and body energy-based medical aesthetic technologies.
Cutera pioneered Nd:YAG technology and has continued to innovate, offering a premium portfolio of products that include Xeo®, truSculpt®, and excel V™. In 2014, the company expanded its product line with two significant additions: excel HR™, which provides high-speed, comfortable hair removal, and enlighten™, the industry's first system combining picosecond and nanosecond wavelengths.
With a presence in over 40 countries and direct operations in North America, France, Australia, Japan, and Hong Kong, Cutera is committed to meeting the evolving needs of the medical aesthetic community. Their solutions are designed to deliver better results, faster and safer than ever before.
The company markets its products under various trademarks, including Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis Plus, Pico-genesis, Titan, truSculpt, and Xeo. Cutera derives the majority of its revenue from the United States but maintains a strong international presence.
Recent achievements include the introduction of innovative products that have set new industry standards. Cutera's focus on research and development ensures that they remain at the forefront of the medical aesthetic technology market, continuously providing advanced solutions to practitioners worldwide.
For the latest updates and relevant information about Cutera's performance, events, and developments, stay tuned to Cutera's news section on StockTitan.
Cutera has announced a partnership with the Adaptive Training Foundation (ATF) to provide truFlex muscle stimulation treatments to adaptive athletes. Supported by Dr. Edward Alvarez, the initiative aims to enhance the strength, muscle tone, and endurance of ATF participants during a nine-week specialized training course called ReDefine. The course includes physical and mental training to help participants redefine their sense of self. A survey study highlighted improvements in areas like the abdomen, glutes, and thighs. David Vobora, ATF Founder, praised the technology for increasing muscle function and body empowerment. Cutera plans to donate the truFlex device to ATF at the end of the year. For more information, visit yourtrubody.com and adaptivetrainingfoundation.org.
Cutera (CUTR) reported Q3 2024 financial results with consolidated revenue of $32.5 million, representing a 30% decrease compared to Q3 2023. The company maintained cash and equivalents of $59.0 million. AviClear showed 16% growth year-over-year in international markets, while global core capital grew 7% sequentially. Gross profit was $1.8 million (6% of revenue), down from $6.5 million (14%) in Q3 2023. Operating loss was $36.2 million. Management reaffirmed full-year revenue guidance of $140-145 million and year-end 2024 cash guidance of approximately $40 million.
Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, has announced that it will report its financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The company's management will host a conference call to discuss these results at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Participants can register for the conference call through a provided link, which will offer dial-in details and a unique PIN upon registration. Alternatively, participants can dial Canada/USA Toll Free: 1-844-763-8274 or +1-647-484-8814. The call will also be webcast and accessible from the Investor Relations section of Cutera's website. A webcast replay will be available approximately one hour after the call ends.
Cutera Inc. (Nasdaq: CUTR) reported Q2 2024 financial results with consolidated revenue of $34.4 million, a 44% decrease compared to Q2 2023. Key highlights include:
- AviClear growth of 41% vs prior year period
- Service growth of 7% vs prior year period
- Cash, cash equivalents, and restricted cash of $84.3 million
- Completion of Q4 2023 corporate restructuring program
- Additional $10 million cost reduction opportunity identified
The company revised its full-year revenue guidance to $140-$145 million and updated cash guidance to approximately $40 million by year-end. Steve Kreider was promoted to SVP, North America, to lead the combined North American commercial organization.
Cutera (Nasdaq: CUTR) has announced an exclusive distribution agreement with L'Oréal Japan Co. to promote, market, sell, and distribute select SkinCeuticals products to medical and physician-led clinics in Japan. The partnership, initially spanning three years with renewal options, aims to expand access to high-quality skincare solutions in the Japanese aesthetics market.
Key points:
- L'Oréal Japan Co. will provide marketing and advertising support
- Cutera KK strengthens its position in the Japanese aesthetics market
- SkinCeuticals products will be introduced in Q4 2023
- Financial impact expected to be immaterial in 2024
Cutera (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, has announced that it will release its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Participants can register for the call using a provided link, which will bypass the operator queue. Alternatively, they can dial in using toll-free numbers. The call will also be webcast from Cutera's Investor Relations website. A replay will be available approximately one hour after the call ends.
Cutera has released new survey data during June’s Acne Awareness Month, highlighting the impact of acne on individuals and the growing interest in modern treatments. The survey, conducted in partnership with EvolveMKD and FocalData, involved 500 U.S. acne sufferers. Key findings include that 90% of respondents experience daily insecurities, 43% worry about never achieving clear skin, and 60% find the struggle to treat acne more distressing than acne itself. The survey also indicates a significant interest in AviClear, Cutera's FDA-cleared energy-based acne treatment device. Half of those aware of AviClear express interest in trying it, and 81% want to learn more about in-office treatments, with lasers being the most considered option. Cutera’s CEO, Taylor Harris, emphasizes the company's commitment to transforming lives through innovative technologies. Additional activities for Acne Awareness Month include an AviClear investor webinar on June 20, 2024, and a sweepstakes offering a $500 prize for sharing acne-related experiences.
Cutera (Nasdaq: CUTR) has appointed Jeryl 'Jeri' Hilleman to its Board of Directors, effective July 12, 2024. Hilleman brings over 30 years of experience in the healthcare industry, with a strong background in financial leadership, strategic planning, and corporate governance. She has served as CFO for multiple public healthcare companies, including Intersect ENT, Ocera Therapeutics, and Amyris. CEO Taylor Harris highlighted her expertise as critical for Cutera's growth and innovation, particularly with products like AviClear. Hilleman has also held significant governance roles, such as Chair of the Board at Omada Health and Audit Committee Chair at NovoCure, Minerva Neurosciences, and others.
Cutera announced an investor webinar to present AviClear, the first FDA-cleared energy device for treating inflammatory acne, on June 20, 2024, at 11 a.m. PDT. The session will cover clinical data, market potential, future studies, and user experiences. Key speakers include CEO Taylor Harris, CTO Michael Karavitis, SVP of Global Marketing Steve Kreider, and dermatologists Dr. David J. Goldberg and Dr. Sonia Batra. The event will conclude with a live Q&A session for analysts and investors. Participants can join via the provided link or phone numbers. A replay will be available on Cutera’s website the next day.
Cutera, a leader in aesthetic and dermatology solutions, announced the granting of 44,500 non-qualified inducement stock options to six employees. Approved by the Compensation Committee of Cutera's Board of Directors, these options have an exercise price of $2.23, matching the closing price of Cutera's stock on the grant date, May 13, 2024.
The vesting schedule is as follows: 25% of the 29,500 stock options granted to five employees will vest annually, with an additional 1/48 vesting monthly, contingent on continued employment. For the remaining 15,000 stock options granted to one employee, 33% will vest annually with 1/36 vesting monthly, also subject to continued employment. These awards are part of Cutera's 2023 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Cutera (CUTR)?
What is the market cap of Cutera (CUTR)?
What does Cutera, Inc. specialize in?
When was Cutera, Inc. established?
What are some of Cutera’s key products?
Where is Cutera, Inc. headquartered?
In how many countries does Cutera have a presence?
What technology did Cutera pioneer?
Where does Cutera derive the majority of its revenue?
What is the significance of the product excel HR™?
What is unique about the enlighten™ system?
How does Cutera stay at the forefront of the industry?
